JP2003501022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003501022A5 JP2003501022A5 JP2001500744A JP2001500744A JP2003501022A5 JP 2003501022 A5 JP2003501022 A5 JP 2003501022A5 JP 2001500744 A JP2001500744 A JP 2001500744A JP 2001500744 A JP2001500744 A JP 2001500744A JP 2003501022 A5 JP2003501022 A5 JP 2003501022A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- amino acid
- seq
- group
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000004474 valine Chemical group 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13617499P | 1999-05-27 | 1999-05-27 | |
| US60/136,174 | 1999-05-27 | ||
| PCT/US2000/011862 WO2000073431A2 (en) | 1999-05-27 | 2000-05-25 | Methods and compositions for measuring ion channel conductance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003501022A JP2003501022A (ja) | 2003-01-14 |
| JP2003501022A5 true JP2003501022A5 (enExample) | 2007-07-12 |
Family
ID=22471672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001500744A Withdrawn JP2003501022A (ja) | 1999-05-27 | 2000-05-25 | イオンチャネルコンダクタンスを測定するための方法およびその組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070238168A1 (enExample) |
| EP (1) | EP1180142A2 (enExample) |
| JP (1) | JP2003501022A (enExample) |
| AU (1) | AU4980200A (enExample) |
| WO (1) | WO2000073431A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| WO2001044283A2 (en) * | 1999-12-14 | 2001-06-21 | Pharmacia & Upjohn Company | Human ion channels |
| GB0003069D0 (en) * | 2000-02-11 | 2000-03-29 | Cambridge Drug Discovery Ltd | Improved assay |
| DE10006309A1 (de) * | 2000-02-12 | 2001-08-23 | Aventis Pharma Gmbh | Verfahren zur Identifizierung von Substanzen, die die Aktivität von hyperpolarisationsaktivierten Kationen-kanälen modulieren |
| AU2001282873A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6479510B2 (en) | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2001282875A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| WO2002061074A1 (fr) * | 2001-01-30 | 2002-08-08 | Takeda Chemical Industries, Ltd. | Nouvelle proteine et adn la comprenant |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| JP2005504058A (ja) | 2001-08-24 | 2005-02-10 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | 疾患の治療のための置換ヘテロアリール−７−アザ［２．２．１］ビシクロヘプタン |
| ATE551340T1 (de) | 2001-10-02 | 2012-04-15 | Pharmacia & Upjohn Co Llc | Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| US6919359B2 (en) | 2001-11-08 | 2005-07-19 | Pfizer Inc | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
| EP1442037A1 (en) | 2001-11-09 | 2004-08-04 | PHARMACIA & UPJOHN COMPANY | Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
| JP2005522456A (ja) | 2002-02-15 | 2005-07-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド |
| JP2005523287A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾患治療用アザビシクロ化合物 |
| AU2003219690A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| WO2003072578A1 (en) * | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| AU2003267174A1 (en) | 2002-05-09 | 2003-11-11 | Memory Pharmaceuticals Corporation | Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells |
| AU2003253686A1 (en) | 2002-08-01 | 2004-02-23 | Pharmacia & Upjohn Company Llc | 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity |
| JP2006526389A (ja) * | 2003-01-07 | 2006-11-24 | ニューロームド テクノロジーズ、インク． | 蛍光ｔ型チャネルアッセイ |
| ATE517176T1 (de) * | 2004-10-15 | 2011-08-15 | Monell Chemical Senses Centre | Verfahren zur kultivierung von geschmackszellen aus säugern |
| EP1917265B1 (en) | 2005-08-22 | 2010-09-29 | Targacept, Inc. | HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF |
| JP5241255B2 (ja) * | 2008-02-01 | 2013-07-17 | 生化学工業株式会社 | 関節痛の評価方法 |
| WO2009140201A1 (en) | 2008-05-12 | 2009-11-19 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| JP5775819B2 (ja) * | 2008-10-09 | 2015-09-09 | ハワード ヒューズ メディカル インスティチュート | 新規なキメラリガンド開口型イオンチャネルおよびその使用方法 |
| WO2011134920A1 (en) | 2010-04-26 | 2011-11-03 | Novartis Ag | Improved cell culture medium |
| AU2018373279B2 (en) | 2017-11-27 | 2024-07-25 | Trames Bio, Inc. | Compositions and methods for neurological diseases |
| CN111378025A (zh) * | 2020-03-26 | 2020-07-07 | 集美大学 | 河豚毒素结合蛋白tfPSTBP2、核苷酸序列、其多克隆抗体及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670113A (en) * | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
| ATE279516T1 (de) * | 1993-03-08 | 2004-10-15 | Merck & Co Inc | Menschliche neuronale nikotin-acetylcholin- rezeptor-verbindungen und methoden ihres einsatzes |
| US6323000B2 (en) * | 1996-12-20 | 2001-11-27 | Clark A. Briggs | Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof |
| US6103537A (en) * | 1997-10-02 | 2000-08-15 | Aclara Biosciences, Inc. | Capillary assays involving separation of free and bound species |
-
2000
- 2000-05-25 JP JP2001500744A patent/JP2003501022A/ja not_active Withdrawn
- 2000-05-25 EP EP00932007A patent/EP1180142A2/en not_active Withdrawn
- 2000-05-25 WO PCT/US2000/011862 patent/WO2000073431A2/en not_active Ceased
- 2000-05-25 AU AU49802/00A patent/AU4980200A/en not_active Abandoned
-
2007
- 2007-02-12 US US11/705,209 patent/US20070238168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003501022A5 (enExample) | ||
| JP2005505579A5 (enExample) | ||
| JP2001520044A5 (enExample) | ||
| JP2001520045A5 (enExample) | ||
| NZ504548A (en) | Polypeptides and nucleic acids encoding human chordin | |
| JP2003515323A5 (enExample) | ||
| PT1265914E (pt) | Polipéptidos relacionados com wnt-1 e ácidos nucleicos que codificam estes polipéptidos | |
| DE69838143D1 (de) | Antimikrobielle peptide | |
| JP2005516996A5 (enExample) | ||
| JP2005502332A5 (enExample) | ||
| WO2002008426A3 (en) | Fh-binding protein of streptococcus pneumoniae | |
| DE602004028266D1 (de) | Angiogene peptide und ihre verwendungen | |
| RU2007119376A (ru) | Тимус - специфический белок | |
| EP1688498A4 (en) | RECOMBINANT PROTEIN WITH CANCER SUPPRESSIVE EFFECT, ITS CODING GENE AND ITS USE | |
| ATE357526T1 (de) | Modifizierte hcv peptid-impfstoffe | |
| JP2003334088A5 (enExample) | ||
| WO2007029262A3 (en) | Compositions and methods using same for the detection of viruses | |
| WO2004064780A3 (en) | Peptide-based angiogenesis inhibitors and methods of use thereof | |
| JP2024118709A5 (enExample) | ||
| JP2006515984A5 (enExample) | ||
| JP2005535281A5 (enExample) | ||
| JP2006510360A5 (enExample) | ||
| WO2007058267A8 (ja) | 新規タンパク質及びそれをコードする遺伝子 | |
| CA2422295A1 (en) | A gene of aluminum-activated malate transporter of a plant and a protein encoded by the gene | |
| DK1425295T3 (da) | Modificerede peptider og deres anvendelse til behandling af autoimmune sygdomme |